Schulze, Marco H.

[["dc.bibliographiccitation.journal","Frontiers in Microbiology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Taverne-Ghadwal, Liliane"],["dc.contributor.author","Kuhns, Martin"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Mbaitolum, Weina Joseph"],["dc.contributor.author","Kersch, Lydia"],["dc.contributor.author","Weig, Michael"],["dc.contributor.author","Bader, Oliver"],["dc.contributor.author","Groß, U."],["dc.date.accessioned","2022-04-01T10:00:45Z"],["dc.date.available","2022-04-01T10:00:45Z"],["dc.date.issued","2022"],["dc.description.abstract","Oral candidiasis remains a common problem in HIV-infected individuals, especially in sub-Saharan Africa. Here, we performed the first study in Chad on the prevalence of oral yeasts carriage and oral candidiasis in HIV-positive subjects from southern Chad and analyzed the influence of HAART, CD4 + T-cell numbers, and antimycotics in 589 patients. These patients were recruited from a specialized medical center for HIV patients in Sarh and from a rural medical health dispensary in the vicinity, including a total of 384 HIV-positive and 205 HIV-negative individuals. Yeasts obtained from oral specimen were identified by MALDI-TOF MS and their antifungal susceptibility profiles determined. The overall prevalence of yeast colonization and symptomatic oral candidiasis in HIV-infected patients was 25.1%. The prevalence of oral candidiasis was higher in untreated than in HAART-treated HIV-positive patients (16% vs. 2%; p  < 0.01). Oral candidiasis was furthermore associated with high fungal burdens of Candida albicans and a CD4 + T-cell number <200/μl. A shift toward non -albicans Candida species was observed under nucleoside-based HAART therapy. Azole antifungal drug resistance was only observed for the intrinsically resistant species Candida krusei and Candida glabrata . Prevalence of oral candidiasis in the studied area was very low. The species distribution was similar to other countries around the world, with C. albicans being dominant. Candida dubliniensis was not isolated. Nucleoside-based HAART therapy significantly reduced oral colonization as well as occurrence of oral candidiasis caused by C. albicans and led to a species shift toward non- albicans species. Antifungal resistance was not yet a concern in Chad."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fmicb.2022.844069"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105503"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1664-302X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Epidemiology and Prevalence of Oral Candidiasis in HIV Patients From Chad in the Post-HAART Era"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","916"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Emerging Infectious Diseases"],["dc.bibliographiccitation.lastpage","919"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Janssen, Hauke"],["dc.contributor.author","Janssen, Iryna"],["dc.contributor.author","Cooper, Paul"],["dc.contributor.author","Kainyah, Clemens"],["dc.contributor.author","Pellio, Theresia"],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Monnheimer, Mathieu"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schulze, Marco H."],["dc.date.accessioned","2020-12-10T18:44:07Z"],["dc.date.available","2020-12-10T18:44:07Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.3201/eid2405.171506"],["dc.identifier.eissn","1080-6059"],["dc.identifier.issn","1080-6040"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78338"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Antimicrobial-Resistant Bacteria in Infected Wounds, Ghana, 20141"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","33"],["dc.bibliographiccitation.journal","Annals of Clinical Microbiology and Antimicrobials"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Kunze, Nils"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Steinmetz, Nicolas"],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Perl, Thorsten"],["dc.date.accessioned","2018-11-07T09:55:53Z"],["dc.date.available","2018-11-07T09:55:53Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: The early beginning of an adequate antibiotic therapy is crucial in hospital-acquired pneumonia (HAP), but depends on the results of conventional microbiological diagnostics (cMD). It was the aim of this study to evaluate the performance and turnaround times of a new point-of-care multiplex polymerase chain reaction (mPCR) system for rapid identification of pathogens and antibiotic resistance markers. We assessed the applicability of the system under real-life conditions in critical ill patients with HAP. Methods: We enrolled forty critical ill patients with clinical signs for HAP into an observational study. Two samples of respiratory secretions were collected during one course of aspiration and cMD and mPCR testing (Unyvero, Curetis AG, Holzgerlingen, Germany) were performed immediately. The mPCR device was operated as a point-of-care system at the intensive care unit. We compared turnaround times, results of pathogen identification and results of antibiotic resistance testing of both methods. Results: Mean turnaround times (min-max) were 6.5 h (4.7-18.3 h) for multiplex PCR and 71 h (37.2-217.8 h) for conventional microbiology (final cMD results, incomplete results neglected). 60 % (n = 24) of the mPCR tests were completely valid. Complete test failure occurred in 10 % (n = 4) and partial test failure occurred in 30 % (n = 12). We found concordant results in 45 % (n = 18) and non-concordant results in 45 % (n = 18) of all patients. 55 % (n = 16) of the results were concordant in patients with a clinical pulmonary infection score (CPIS) > 5 (n = 29). Concordant results included three cases of multidrug resistant bacteria. MPCR frequently detected antibiotic resistance markers that were not found by cMD. Conclusions: Unyvero allowed point-of-care microbial testing with short turnaround times. The performance of the system was poor. However, an improved system with a more reliable performance and an extended microbial panel could be a useful addition to cMD in intensive care medicine."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2015"],["dc.identifier.doi","10.1186/s12941-015-0091-3"],["dc.identifier.isi","000356592600001"],["dc.identifier.pmid","26071191"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36848"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1476-0711"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Point-of-care multiplex PCR promises short turnaround times for microbial testing in hospital-acquired pneumonia - an observational pilot study in critical ill patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","911"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","European Journal of Clinical Microbiology & Infectious Diseases"],["dc.bibliographiccitation.lastpage","915"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Grau, Imma"],["dc.contributor.author","Ardanuy, C."],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Linares, Josefina"],["dc.contributor.author","Pallares, Roman"],["dc.date.accessioned","2018-11-07T10:24:43Z"],["dc.date.available","2018-11-07T10:24:43Z"],["dc.date.issued","2017"],["dc.description.abstract","Polymicrobial bacteraemia involving Streptococcus pneumoniae and other bacteria (e.g. Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenza, viridans streptococci, Salmonella spp.) occurred in 3.4% of our pneumococcal bacteraemia cases. Compared with 308 controls (monomicrobial bacteraemia), the 77 polymicrobial cases included more males (83 vs 62%, p = 0.001), had serious underlying diseases (100 vs 80%, p < 0.001), abdominal infection (18 vs 5%, p < 0.001), nosocomial infection (33 vs 8%, p < 0.001), shock (40 vs 13%, p < 0.001), and higher mortality (52 vs 18%, p < 0.001). Clinicians must be aware that some patients with pneumococcal bacteraemia may have other bacteria in their blood, which would confer higher mortality and may lead to inappropriate or incomplete antibiotic therapy."],["dc.identifier.doi","10.1007/s10096-016-2885-4"],["dc.identifier.isi","000399694500020"],["dc.identifier.pmid","28054228"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42708"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1435-4373"],["dc.relation.issn","0934-9723"],["dc.title","Polymicrobial pneumococcal bacteraemia: a case-control study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","The Thoracic and Cardiovascular Surgeon"],["dc.contributor.author","Saha, Shekhar"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Kutschka, Ingo"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Niehaus, Heidi"],["dc.date.accessioned","2022-04-01T10:02:45Z"],["dc.date.available","2022-04-01T10:02:45Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Objective The rising incidence of infective endocarditis (IE) accompanied by the de-escalation of antibiotic prophylaxis and the complexity of surgical treatment makes IE a daunting foe. We reviewed all patients who underwent cardiac surgery for IE at our institution with a focus on causative organisms and infective foci. Methods A review of 3,952 consecutive patients who underwent cardiac surgery at our institution between January 2013 and December 2017 revealed 160 patients (4%) who were operated for IE. Results The predominantly affected valves were the aortic (30%) and mitral valve (26.9%) as well as a combination of both (8.8%). A total of 28.8% of patients suffered from prosthetic valve endocarditis (PVE). The most frequently identified causative organisms were Staphylococcus (45.7%), Streptococcus (27.5%), and Enterococcus species (16.7%), which was predominantly associated with PVE (p = 0.050). In 13.1% of patients, a causative organism has not been detected. The most frequent infective foci were dental (15%), soft-tissue infections (15%), spondylodiscitis (10%), and infected intravascular implants (8.8%). Relevant predisposing factors were immunosuppression (9.4%) and intravenous drug abuse (4.4%). Septic cerebral infarctions were diagnosed in 28.8% of patients. Postoperative mortality was 22.5%. Conclusions As the bacterial spectrum and the infective foci are still the “old acquaintances,” and with regard to the increasing incidence of IE, current risk–benefit evaluations concerning antibiotic prophylaxis may need to be revisited."],["dc.identifier.doi","10.1055/s-0041-1740540"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105997"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1439-1902"],["dc.relation.issn","0171-6425"],["dc.title","Bacterial Spectrum and Infective Foci in Patients Operated for Infective Endocarditis: Time to Rethink Strategies?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","60"],["dc.bibliographiccitation.journal","TrAC Trends in Analytical Chemistry"],["dc.bibliographiccitation.lastpage","70"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Hoellein, Ludwig"],["dc.contributor.author","Kaale, Eliangiringa"],["dc.contributor.author","Mwalwisi, Yonah H."],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Holzgrabe, Ulrike"],["dc.date.accessioned","2018-11-07T10:18:45Z"],["dc.date.available","2018-11-07T10:18:45Z"],["dc.date.issued","2016"],["dc.description.abstract","Counterfeit and substandard medicines still constitute a worldwide problem and do not only affect health-care systems in low and middle income countries but also in the industrialized world. Whereas in the developed world the quality of pharmaceutical preparations is assured by a dense network of quality control laboratories utilizing modern analytical techniques the situation is completely diverse in resource constraint countries. Implementing full monograph testing according to the American or the European Pharmacopoeia represents an extreme challenge. The respective quality control organs easily become overburdened and face central problems when supplying immaculate medicines. This review collected information on the prevalence of counterfeit and substandard pharmaceuticals in Tanzania and discusses suitable analytical approaches for their analysis, e.g. non-sophisticated HPLC, low-field NMR, capillary electrophoresis, or vibrational spectroscopy. Due to the limited validity and reproducibility of field assay kits like the Minilab (R) the impact of precise, simple, and robust analytical methods is highlighted. (C) 2015 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.trac.2015.11.009"],["dc.identifier.isi","000370096800006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41516"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","1879-3142"],["dc.relation.issn","0165-9936"],["dc.title","Routine quality control of medicines in developing countries: Analytical challenges, regulatory infrastructures and the prevalence of counterfeit medicines in Tanzania"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","157"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Breast Cancer Research and Treatment"],["dc.bibliographiccitation.lastpage","166"],["dc.bibliographiccitation.volume","87"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Simon, Alfred"],["dc.contributor.author","Binder, L."],["dc.contributor.author","Hagemann, T."],["dc.contributor.author","Schulz, M."],["dc.contributor.author","Emons, G."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Einspanier, Almuth"],["dc.date.accessioned","2018-11-07T10:45:48Z"],["dc.date.available","2018-11-07T10:45:48Z"],["dc.date.issued","2004"],["dc.description.abstract","Relaxin (RLX) is known to induce remodeling of benign stromal tissues through upregulation of matrix metalloproteases (MMPs). Recently, we could show that RLX also induces MMPs in breast cancer cells and enhances in vitro invasiveness. To investigate its potential role for progression of breast cancer in vivo, RLX serum concentrations were determined in 160 breast cancer patients during post-surgical follow-up. RLX concentrations in cancer patients were significantly higher than in a control population of healthy blood donors and patients with various other diseases (0.47 versus 0.29 ng/ml, p < 0.0001). There was a significant difference between patients with metastases (0.62 ng/ml) and those without (0.38 ng/ml, p < 0.0001). Overall survival was shorter in RLX-positive (>0.4 ng/ml) than in RLX-negative patients (p = 0.016). Cox regression analysis showed that RLX was not an independent variable, in contrast to metastatic disease and primary lymph node involvement. Taken together, the detection of elevated RLX concentrations especially in patients with metastases supports the assumption that there is a role for RLX in tissue remodeling during breast cancer progression."],["dc.identifier.doi","10.1023/B:BREA.0000041622.30169.16"],["dc.identifier.isi","000223914900005"],["dc.identifier.pmid","15377840"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47592"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Kluwer Academic Publ"],["dc.relation.issn","0167-6806"],["dc.title","Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","144"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Hepatology"],["dc.bibliographiccitation.lastpage","159"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Nussler, A."],["dc.contributor.author","Konig, Sarah"],["dc.contributor.author","Ott, M."],["dc.contributor.author","Sokal, E."],["dc.contributor.author","Christ, B."],["dc.contributor.author","Thasler, W."],["dc.contributor.author","Brulport, M."],["dc.contributor.author","Gabelein, G."],["dc.contributor.author","Schormann, W."],["dc.contributor.author","Schulze, M."],["dc.contributor.author","Ellis, E."],["dc.contributor.author","Kraemer, M."],["dc.contributor.author","Nocken, F."],["dc.contributor.author","Fleig, W."],["dc.contributor.author","Manns, M."],["dc.contributor.author","Strom, S. C."],["dc.contributor.author","Hengstler, Jan G."],["dc.date.accessioned","2018-11-07T09:36:53Z"],["dc.date.available","2018-11-07T09:36:53Z"],["dc.date.issued","2006"],["dc.description.abstract","In recent years the interest in liver cell therapy has been increasing continuously, since the demand for whole liver transplantations in human beings far outweighs the supply. From the clinical point of view, transplantation of hepatocytes or hepatocyte-like cells may represent an alternative to orthotopic liver transplants in acute liver failure, for the correction of genetic disorders resulting in metabolically deficient states, and for late stage liver disease such as cirrhosis. Although the concept of cell therapy for various diseases of the liver is widely accepted, the practical approach in humans often remains difficult. An international expert panel critically discussed the recent published data on clinical and experimental hepatocyte transplantation and the possible role of stem cells in liver tissue repair. This paper aims to summarise the present status of cell based therapies for liver diseases and to identify areas of future preclinical and clinical research. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.jhep.2006.04.002"],["dc.identifier.isi","000238782200016"],["dc.identifier.pmid","16730092"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32713"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0168-8278"],["dc.title","Present status and perspectives of cell-based therapies for liver diseases"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1499"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Clinical Microbiology"],["dc.bibliographiccitation.lastpage","1500"],["dc.bibliographiccitation.volume","50"],["dc.contributor.author","Tappe, Dennis"],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Oesterlein, Anett"],["dc.contributor.author","Abele-Horn, Marianne"],["dc.contributor.author","Baron, Stefan"],["dc.contributor.author","Durchholz, Daniel"],["dc.contributor.author","Langen, Heinz-Jakob"],["dc.contributor.author","Jany, Berthold"],["dc.contributor.author","Schoen, Christoph"],["dc.date.accessioned","2018-11-07T09:11:46Z"],["dc.date.available","2018-11-07T09:11:46Z"],["dc.date.issued","2012"],["dc.description.abstract","Spondylodiscitis caused by Campylobacter species is a rare disease which is most often caused by Campylobacter fetus. We report a case of culture-negative spondylodiscitis and a psoas abscess due to Campylobacter jejuni in a 68-year-old woman, as revealed by 16S rRNA gene and Campylobacter-specific PCRs from biopsied tissue."],["dc.identifier.doi","10.1128/JCM.06275-11"],["dc.identifier.isi","000302148700070"],["dc.identifier.pmid","22259199"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26796"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Microbiology"],["dc.relation.issn","0095-1137"],["dc.title","Molecular Detection of Campylobacter jejuni as a Cause of Culture-Negative Spondylodiscitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","889"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","893"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Fabri, Mario"],["dc.contributor.author","Schlapbach, Christoph"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2020-12-10T18:27:20Z"],["dc.date.available","2020-12-10T18:27:20Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1111/ddg.13925_g"],["dc.identifier.eissn","1610-0387"],["dc.identifier.issn","1610-0379"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76313"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Diagnose mykobakterieller Hautinfektionen"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]